Amivantamab, an anti-epidermal growth factor receptor (EGFR)-c-MET bispecific antibody, was approved by the FDA in 2021 for the treatment of non-small-cell lung carcinoma (NSCLC) patients harboring insertion mutations in the EGFR exon 20. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.